This relatively high efficacy of the blood-derived CD8+ T cells was associated with characteristics of undifferentiated cells in the tumor-specific population such as a much higher percentage of TCF1+ cells, a much lower PD1 MFI, a much lower percentage of TIM3+ cells, a lower apoptosis propensity and a higher proliferative capacity and polyfunctionality than tumor-specific CD8+ TILs. This evidence concerns the gene CD8A and neoplasm.